More recently, the Nrf2 activator dimethyl fumarate (DMF), exploited for its anti-inflammatory and antioxidant effects, was observed to modulate the inflammatory response upon LPS stimulation in both CF and non-CF bronchial epithelial cells. Here, NFE2L2 is linked to cystic fibrosis.